Evidence map›Paper›PMID 36659929›Full record

ArticleComputational and structural biotechnology journal2023

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues.

Jiayu Zhang, Tong Lu, Shiqi Lu, Shuaijun Ma, Donghui Han, Keying Zhang, Chao Xu, Shaojie Liu, Lunbiao Gan, Xinjie Wu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Article
  3. Prospective evaluation ofAnnals of nuclear medicine · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Selective Targeting of Tip Endothelial Cells as a Therapeutic Strategy for Tumor Angiogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jiayu ZhangDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Tong LuDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Shiqi LuInstitute of Medical Research, Northwestern Polytechnical University, Xi'an, China.
Shuaijun MaDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Donghui HanDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Keying ZhangDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Chao XuDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Shaojie LiuDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Lunbiao GanInstitute of Medical Research, Northwestern Polytechnical University, Xi'an, China.
Xinjie WuInstitute of Medical Research, Northwestern Polytechnical University, Xi'an, China.
Fa YangDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Weihong WenInstitute of Medical Research, Northwestern Polytechnical University, Xi'an, China.
Weijun QinDepartment of Urology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Xijing Hospital · CNNorthwestern Polytechnical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial cells (ECs) play an important role in tumor progression. Currently, the main target of anti-angiogenic therapy is the vascular endothelial growth factor (VEGF) pathway. Some patients do benefit from anti-VEGF/VEGFR therapy; however, a large number of patients do not have response or acquire drug resistance after treatment. Moreover, anti-VEGF/VEGFR therapy may lead to nephrotoxicity and cardiovascular-related side effects due to its action on normal ECs. Therefore, it is necessary to identify targets that are specific to tumor ECs and could be applied to various cancer types. We integrated single-cell RNA sequencing data from six cancer types and constructed a multi-cancer EC atlas to decode the characteristic of tumor ECs. We found that tip-like ECs mainly exist in tumor tissues but barely exist in normal tissues. Tip-like ECs are involved in the promotion of tumor angiogenesis and inhibition on anti-tumor immune responses. Moreover, tumor cells, myeloid cells, and pericytes are the main sources of pro-angiogenic factors. High proportion of tip-like ECs is associated with poor prognosis in multiple cancer types. We also identified that prostate-specific membrane antigen (PSMA) is a specific marker for tip-like ECs in all the cancer types we studied. In summary, we demonstrate that tip-like ECs are the main differential EC subcluster between tumors and normal tissues. Tip-like ECs may promote tumor progression through promoting angiogenesis while inhibiting anti-tumor immune responses. PSMA was a specific marker for tip-like ECs, which could be used as a potential target for the diagnosis and treatment of non-prostate cancers.

Indexed as

BRCA, Breast invasive carcinomaCESC, Cervical squamous cell carcinoma and endocervical adenocarcinomaCRC, Colorectal cancerECs, Endothelial cellsEndothelial cellsGC, Gastric cancerHNSC, Head and Neck squamous cell carcinomaKICH, Kidney chromophobeKIRC, Kidney renal clear cell carcinomaKIRP, Kidney renal papillary cell carcinomaLC, Lung cancerLIHC, Liver hepatocellular carcinomaLUAD, Lung adenocarcinomaLUSC, Lung squamous cell carcinomaOVC, Ovarian cancerOV, Ovarian serous cystadenocarcinomaPAAD, Pancreatic adenocarcinomaPDAC, Pancreatic ductal adenocarcinomaPRAD, Prostate adenocarcinomaPSMA, Prostate-specific membrane antigenRCC, Renal cell carcinomaREAD, Rectum adenocarcinomascRNA-seq, Single-cell RNA sequencingSingle-cell RNA sequencingSTAD, Stomach adenocarcinomaTME, Tumor microenvironmentTumor microenvironmentVEGF, Vascular endothelial growth factor

Identifiers

PMID36659929
PMCPMC9826920
OpenAlexW4313530657

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.